The Survival of Osteosarcoma Patients 10 Years Old or Younger Is Not Worse than the Survival of Older Patients:A Retrospective Analysis
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to assess whether a young age at the time of diagnosis with osteosarcoma has value to predict the prognosis. Materials and Methods: Sixty-seven children with stage II osteosarcoma were stratified according to the age of 10. There were 32 preadolescents (≤10 years) and 35 adolescents (10＜age≤15 years). The patients were analyzed for their clinical characteristics, the histologic response to preoperative chemotherapy, event-free survival (EFS) and the patterns of relapse. Results: After a median follow-up of 54 months (range: 6∼153 months), the 5-year EFS of the preadolescent and adolescent groups was 64.5±9.3% and 58.2±9.1%, respectively, and age did not have any statistical significance for survival (p=0.55). Cox regression analysis revealed that both the serum level of alkaline phosphatase and the histologic response to preoperative chemotherapy were significantly related to survival of the 67 patients. Those patients aged less than 7 years responded poorly to preoperative chemotherapy and their rate of amputation was 43%. However, their 5-year EFS was not statistically different from the older patients (57.1±18.7 vs 67.7±6.3%, respectively, p=0.58). Conclusions: We could not find any statistical difference in the clinical characteristics and survival from osteosarcoma for the preadolescents and adolescents, so the current approach of having the same protocol for both groups of patients seems to be reasonable. (Cancer Res Treat. 2007;39:160-164)
Abstract
Purpose: This study aimed to assess whether a young age at the time of diagnosis with osteosarcoma has value to predict the prognosis. Materials and Methods: Sixty-seven children with stage II osteosarcoma were stratified according to the age of 10. There were 32 preadolescents (≤10 years) and 35 adolescents (10＜age≤15 years). The patients were analyzed for their clinical characteristics, the histologic response to preoperative chemotherapy, event-free survival (EFS) and the patterns of relapse. Results: After a median follow-up of 54 months (range: 6∼153 months), the 5-year EFS of the preadolescent and adolescent groups was 64.5±9.3% and 58.2±9.1%, respectively, and age did not have any statistical significance for survival (p=0.55). Cox regression analysis revealed that both the serum level of alkaline phosphatase and the histologic response to preoperative chemotherapy were significantly related to survival of the 67 patients. Those patients aged less than 7 years responded poorly to preoperative chemotherapy and their rate of amputation was 43%. However, their 5-year EFS was not statistically different from the older patients (57.1±18.7 vs 67.7±6.3%, respectively, p=0.58). Conclusions: We could not find any statistical difference in the clinical characteristics and survival from osteosarcoma for the preadolescents and adolescents, so the current approach of having the same protocol for both groups of patients seems to be reasonable. (Cancer Res Treat. 2007;39:160-164)
참고문헌 (17)
- Grovas A, "The national cancer data base report on patterns of childhood cancers in the united states", 80, pp.2321~2332 (1997)
- van den Berg H, "Acute lymphoblastic leukaemia in puberty and adolescence", 11, pp.1375~1379 (2000)
- Silverman LB, "Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment", 10, pp.290~296 (2003)
- London WB, "Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the children's oncology group", 23, pp.6459~6465 (2005)
- Maris JM, "Neuroblastoma", 369, pp.2106~2120 (2007)
- Buckley JD, "Epidemiology of osteosarcoma and ewing's sarcoma in childhood: a study of 305 cases by the children's cancer group", 83, pp.1440~1448 (1998)
- Scranton PE, "Yunis EJ. Prognostic factors in osteosarcoma. A review of 20 year's experience at the university of pittsburgh health center hospitals. Cancer. 1975;36", pp.2179~91
- Winkler K, "et al. Neoadjuvant chemotherapy of osteosarcoma Results of a randomized cooperative trial with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6", pp.329~82 37
- Fuchs N, "Long-term results of the co-operative german- austrian-swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs", 9, pp.893~899 (1998)
- McKenna RJ, "Higinbotham NL. Osteogenic sarcoma in children. Calif Med. 1965;103", pp.165~70
- Winkler K, "et al. Neoadjuvant chemotherapy for osteogenic sarcoma Results of a cooperative German", Austrian study. J Clin Oncol. 1984;2, 617~24
- Hudson M, "and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8" (1988)
- Perez-Atayde AR, "Vawter GF. Osteosarcoma in young children. Cancer. 1991;67", pp.638~42
- Rytting M, "Osteosarcoma in preadolescent patients", 373, pp.39~50 (2000)
- Greene FL, "The American joint committee on cancer: Updating the strategies in cancer staging", 87, pp.13~15 (2002)
- Rosen G, "eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106", pp.55~67
- Bacci G, "Primary high-grade osteosarcoma: comparison between preadolescent and older patients", 27, pp.129~134 (2005)